Drugs / EBT-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05144386 | Jan 2022 → Nov 2024 | HIV infectious disease | Excision BioTherapeutics | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05143307 Background | Jul 2023 → Jan 2037 expected | HIV infectious disease | Excision BioTherapeutics | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBT-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05144386 ↗ |
| Modality | CRISPR / gene editing | “clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system” NCT05144386 ↗ |
| Route | Intravenous | “for intravenous (IV) administration” NCT05144386 ↗ |